Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)
PRIMA BIOMED TO MAINTAIN
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) the Company has received notification from the Listing
Qualifications Department of the NASDAQ Stock Market indicating that the Company s American Depositary Shares have maintained a closing bid price of US$1.00 per share or greater for 10 consecutive business days from 28 December 2016 to
11 January 2017. Accordingly, the Company has regained compliance with NASDAQ Listing Rule 5450(a)(1) (the Minimum Bid Price Rule ) and the Company s American Depositary Shares will remain listed on the NASDAQ Global Market.
Prima BioMed is a globally
active biotechnology company that is striving to become a leader in the development of immunotherapeutic products. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and
to maximise value to shareholders.
Prima s current lead product is IMP321, based on the LAG-3 immune control
mechanism which plays a vital role in the regulation of the T cell immune response. IMP321 is a soluble LAG-3Ig fusion protein and an APC activator boosting T cell responses. IMP321 is currently in a Phase II
clinical trial as a chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT 02614833) and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov identifier
NCT 02676869). Additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by Prima s large pharmaceutical partners. Prima is also
developing an agonist of LAG-3 (IMP761) for autoimmune disease.
Prima BioMed is listed on the Australian
Securities Exchange and on the NASDAQ in the US. For further information please visit www.primabiomed.com.au.
For further information please
Mr Matthew Beck, The
+1 (646) 378-2933; mbeck@troutgroup.com
Australia Investor/Media:
Mr Matthew Gregorowski,
+61 2 8234 0100; mgregorowski@citadelmagnus.com
Prima BioMed Ltd, Level 12, 95 Pitt Street, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889